🏛️ Verified NIH Record • Updated 2025-11-04
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD (NCT07116889)
A Phase 1 First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GB-0895 in Adults With Mild to Moderate Asthma or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Generate Biomedicines
🩺 Plain-English Summary (8th-Grade Level)
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Who can join: Review the eligibility criteria below.
Location: Alcanza — DeLand, Florida
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Alcanza — DeLand, Florida
- Miami Research Institute of South Florida — Miami, Florida
- Omega Research — Orlando, Florida
- Nucleus Network — Saint Paul, Minnesota
- Southeastern Research Center — Winston-Salem, North Carolina
- DM Clinical Research — Tomball, Texas
- Charite Research Organization GmbH — Berlin,
- IKF Pneumologie — Frankfurt,
- Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM) — Hanover,
- Hammersmith Medicines Research — London,
- Queen Anne Street Medical Center — London,
- Medicines Evaluation Unit (MEU) — Manchester,
- Simbec-Orion Clinical Development — Merthyr Tydfil,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.